HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gherardi, M. M. Articles by Esteban, M. Search for Related Content PubMed PubMed Citation Articles by Gherardi, M. M. Articles by Esteban, M. Agricola Articles by Gherardi, M. M. Articles by Esteban, M.

Recombinant poxviruses as mucosal vaccine vectors

¹ National Reference Center for AIDS, Department of Microbiology, School of Medicine, University of Buenos Aires, Paraguay 2155 piso 11 (C1121ABG), Buenos Aires, Argentina
² Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, CSIC, Ciudad Universitaria Cantoblanco, 28049 Madrid, Spain

Correspondence
Mariano Esteban
mesteban{at}cnb.uam.es
M. Magdalena Gherardi
mgherardi{at}fmed.uba.ar

The majority of infections initiate their departure from a mucosal surface, such as Human immunodeficiency virus (HIV), a sexually transmitted virus. Therefore, the induction of mucosal immunity is a high priority in the development of vaccines against mucosal pathogens. The selection of an appropriate antigen delivery system is necessary to induce an efficient mucosal immune response. Poxvirus vectors have been the most intensively studied live recombinant vector, and numerous studies have demonstrated their ability to induce mucosal immune responses against foreign expressed antigens. Previous studies have demonstrated that recombinants based on the attenuated modified vaccinia virus Ankara (MVA) vector were effective in inducing protective responses against different respiratory viruses, such as influenza and respiratory syncytial virus, following immunization via mucosal routes. Recent studies performed in the murine and macaque models have shown that recombinant MVA (rMVA) does not only stimulate HIV-specific immunity in the genital and rectal tracts following mucosal delivery, but can also control simian/human immunodeficiency viraemia and disease progression. In addition, a prime-boost vaccination approach against tuberculosis emphasized the importance of the intranasal rMVA antigen delivery to induce protective immunity against Mycobacterium tuberculosis. The aim of this review is to summarize the studies employing recombinant poxviruses, specifically rMVA as a mucosal delivery vector. The results demonstrate that rMVAs can activate specific immune responses at mucosal surfaces, and encourage further studies to characterize and improve the MVA mucosal immunogenicity of poxvirus vectors.

Published online ahead of print on 30 August 2005 as DOI 10.1099/vir.0.81181-0.

This article has been cited by other articles:

				D. B. Gammon and D. H. Evans The 3'-to-5' Exonuclease Activity of Vaccinia Virus DNA Polymerase Is Essential and Plays a Role in Promoting Virus Genetic Recombination J. Virol., May 1, 2009; 83(9): 4236 - 4250. [Abstract] [Full Text] [PDF]

				W. Kastenmuller, G. Gasteiger, L. Stross, D. H. Busch, and I. Drexler Cutting Edge: Mucosal Application of a Lyophilized Viral Vector Vaccine Confers Systemic and Protective Immunity toward Intracellular Pathogens J. Immunol., March 1, 2009; 182(5): 2573 - 2577. [Abstract] [Full Text] [PDF]

				P. Mooij, S. S. Balla-Jhagjhoorsingh, G. Koopman, N. Beenhakker, P. van Haaften, I. Baak, I. G. Nieuwenhuis, I. Kondova, R. Wagner, H. Wolf, et al. Differential CD4+ versus CD8+ T-Cell Responses Elicited by Different Poxvirus-Based Human Immunodeficiency Virus Type 1 Vaccine Candidates Provide Comparable Efficacies in Primates J. Virol., March 15, 2008; 82(6): 2975 - 2988. [Abstract] [Full Text] [PDF]